Adeno-associated virus (AAV) vectors are important gene delivery tools for gene therapies. To ensure that novel treatments can be effective and can reach as many patients as possible, AAV vectors must be produced at high quality and high titres â€“ and manufacturing approaches must keep pace with an increased demand for treatments.
AAV quality and titre can be improved by optimizing the plasmids used in their production, and by integrating these plasmids into a robust transient manufacturing platform. Working with a partner organization that can take a novel gene therapy from early plasmid engineering through preclinical and clinical GMP manufacture will help innovators ensure quality and efficiency from start to finish.
- The challenges of ensuring high quality and titre for AAV vector manufacture.
- The optimization of AAVEX™ plasmids for viral vector quality and titre.
- The advantages of the WuXi Advanced Therapies transient AAV production system for GMP-grade manufacture.
Just fill out the form below to watch the recorded webcast now.